Morales-Barrera, Rafael http://orcid.org/0000-0001-7398-0685
Villacampa, Guillermo
Vidal, Natalia
Figols, Mariona
Giner, Julia
Bonfill, Teresa
Suárez, Cristina
Díaz, Nely
Mateo, Joaquín
González, Macarena
Domenech, Montserrat
Puente, Javier
Carles, Joan
Article History
Received: 7 February 2023
Accepted: 29 April 2023
First Online: 22 May 2023
Declarations
:
: The authors declare the following financial interests/personal. RMB: (all unrelated in the last 3 years): Consulting or advisory and/or speakers bureaus for Sanofi Aventis, AstraZeneca, Merck Sharp & Dohme, Astellas, BMS and received travel and accommodations expenses from Roche, Sanofi Aventis, Astellas, Janssen, Merck Sharp & Dohme, Bayer, and Pfizer. GV: has received research honoraria for speaker activities from MSD and advisory role from AstraZeneca. NV: Speaker bureaus for Sanofi, AstraZeneca, Astellas, Janssen, Roche, MSD, Bristol. MF: Advisory and/or speakers bureaus for BMS, Ipsen, Merck and Pfizer. JG: nothing to declare. TB: Advisory and/or speakers bureaus for Merck, Roche, BMS, Pfizer, Astellas and received travel and accommodations expenses from Roche, MSD, Ipsen, Merck and Bayer. CS: Consulting or advisory and/or speakers bureaus for Astellas, Bayer, BMS, Roche, Ipsen, Merck Sharp & Dohme, Novartis, Pfizer, Sanofi Aventis. ND: Travel and accommodations expenses from Sanofi Aventis and Pfizer. JM: has received honoraria and/or acted as consulting or advisory role for AstraZeneca, Roche, MSD, Amgen and Pfizer; JM is also the PI of grants by AstraZeneca and Pfizer to VHIO as institution. MG: Travel and accommodations expenses from Roche, Astellas, Ipsen and Pfizer. MD: Consulting or advisory and/or speakers bureaus for Sanofi Aventis, Bristol-Myers Squibb, Pfizer and received travel and accommodations expenses from Sanofi and Lilly. JP: Honoraria from Pfizer, Bristol-Myers Squibb, Ipsen, AstraZeneca, Roche, MSD Oncology, Janssen-Cilag, Astellas Pharma, EUSA Pharma, Eisai, Pierre Fabre, Sanofi, and Bayer; consulting or advisory role from Pfizer, Astellas Pharma, Janssen-Cilag, Merck Sharpe & Dohme, Bayer, Roche, Bristol-Myers Squibb, Clovis Oncology, Ipsen, Eisai, and Sanofi; research funding from Astellas Pharma and Pfizer; travel/accommodations/expenses from Pfizer, Roche, Janssen-Cilag, Bristol-Myers Squibb, and MSD Oncology. JC: Consulting: Astellas Pharma, AstraZeneca, Bayer, Bristol-Myers Squibb, Johnson & Johnson, MSD Oncology, Novartis (AAA), Pfizer, Roche, Sanofi. Speakers bureaus: Bayer, Asofarma, Astellas, Janssen Fundings / Grants to out institution: AB Science, Aragon Pharmaceuticals, Arog Pharmaceuticals, INC, Astellas Pharma., AstraZeneca AB, Aveo Pharmaceuticals INC, Bayer AG, Blueprint Medicines Corporation, BN Immunotherapeutics INC, Boehringer Ingelheim España, S.A., Bristol-Myers Squibb International Corporation (BMS), Clovis Oncology, INC, Cougar Biotechnology INC, Deciphera Pharmaceuticals LLC, Exelixis INC, F. Hoffmann-La Roche LTD, Genentech INC, Glaxosmithkline, SA, Incyte Corporation, Janssen-Cilag International NV, Karyopharm Therapeutics INC., Laboratories Leurquin Mediolanum SAS, Lilly, S.A., Medimmune, Millennium Pharmaceuticals, INC., Nanobiotix SA, Novartis Farmacéutica, S.A., Pfizer, S.L.U, Puma Biotechnology, INC, Sanofi-Aventis, S.A., SFJ Pharma LTD. II, Teva Pharma S.L.U.
: The study was approved by the Ethics Committee at Vall d’Hebron University Hospital (PR[AG]490/2021). All the patients who were alive at the time of the analysis signed the informed consent form.